OrbiMed’s Rhythm Pharmaceuticals RYTM Stock Holding History

OrbiMed’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$27.3M	Buy	314,100 +74,300	+31%	+$7.23M	0.54%	51
2025 Q4	$25.7M	Buy	239,800 +24,648	+11%	+$2.61M	0.52%	54
2025 Q3	$21.7M	Sell	215,152 -33,360	-13%	-$3.1M	0.51%	52
2025 Q2	$15.7M	Sell	248,512 -131,488	-35%	-$8.05M	0.39%	47
2025 Q1	$20.1M	Sell	380,000 -20,000	-5%	-$1.11M	0.48%	44
2024 Q4	$22.4M	Sell	400,000 -35,900	-8%	-$1.98M	0.46%	49
2024 Q3	$22.8M	Sell	435,900 -268,942	-38%	-$12.9M	0.41%	60
2024 Q2	$28.9M	Hold	704,842	–	–	0.57%	47
2024 Q1	$30.5M	Buy	704,842 +168,200	+31%	+$7.36M	0.56%	49
2023 Q4	$24.7M	Sell	536,642 -47,000	-8%	-$1.48M	0.49%	58
2023 Q3	$13.4M	Buy	+583,642	New	+$13.1M	0.28%	73
2019 Q3	–	Sell	-787,300	Closed	-$17.3M	–	134
2019 Q2	$17.3M	Hold	787,300	–	–	0.27%	75
2019 Q1	$21.6M	Sell	787,300 -141,200	-15%	-$4.06M	0.33%	71
2018 Q4	$25M	Sell	928,500 -112,853	-11%	-$3.12M	0.46%	62
2018 Q3	$30.4M	Sell	1,041,353 -1,023,647	-50%	-$32.3M	0.37%	71
2018 Q2	$64.6M	Sell	2,065,000 -836,295	-29%	-$22.9M	0.77%	43
2018 Q1	$57.7M	Hold	2,901,295	–	–	0.72%	48
2017 Q4	$43.5M	Buy	+2,901,295	New	+$76.7M	0.55%	56

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

OrbiMed's RYTM Position: Q1 2026 in Review

OrbiMed increased its Rhythm Pharmaceuticals (RYTM) stake by 31% in Q1 2026, buying an estimated $7.23M and bringing the position to 314,100 shares worth $27.3M. The position accounts for 0.54% of the portfolio, ranked #51.

OrbiMed first reported a position in RYTM in Q4 2017 and has held it in 18 quarters since. The position peaked at $64.6M in Q2 2018. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

OrbiMed held 314,100 shares of Rhythm Pharmaceuticals worth $27.3M as of Q1 2026.
OrbiMed bought 74,300 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $7.23M.
Rhythm Pharmaceuticals made up 0.54% of OrbiMed's portfolio in Q1 2026, its #51 holding.
OrbiMed first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 18 quarters since.
OrbiMed's Rhythm Pharmaceuticals position peaked at $64.6M in Q2 2018.
285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.